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Background
Ultra-pure ethyl-eicosapentaenoic acid (ethyl-EPA) is a
semi-synthetic, ethyl ester of the long-chain fatty acid
eicosapentaenoic acid which has been shown to be asso-
ciated with clinical improvement in motor functioning
in Huntington’s disease. The aim was to determine the
extent to which it might reduce the rate of progress of
cerebral atrophy.
Materials and methods
High-resolution MRI cerebral scanning was carried out
at baseline, six months and one year in 30 patients with
stage I or II Huntington’s disease who took part in a
randomized, double-blind, placebo-controlled trial of 2 g
daily ethyl-EPA or liquid paraffin, using a 1.0 T Picker
HPQ scanner. For each subject and each pair of T1
images, the two-timepoint percentage brain volume
change was estimated in a double-blind fashion using
SIENA (Structural Image Evaluation, using Normali-
sation, of Atrophy), Version 2.5, part of the FSL (version
4.0) comprehensive library of analysis tools.
Results
Overall, patients treated with ethyl-EPA had a reduced
mean rate of atrophy in all comparisons compared with
the placebo group. There was no significant effect of age
at the time of scanning on these results. Areas of signifi-
cant group-level reduction in brain atrophy between
patients receiving ethyl-EPA and those receiving placebo
were found. Significant changes were observed at the
head of the caudate nucleus and the posterior thalamus.
Conclusions
Treatment with ethyl-EPA is associated with significant
reduction in brain atrophy in Huntington’s disease, par-
ticularly in the head of the caudate and the posterior
thalamus. No other drug tested in HD has shown this
effect.
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